Vendor Intelligence Report: Loti Labs

Executive summary

Across 32 Finnrick lab tests, Loti Labs posts a 47% overall pass rate, with 15 pass / 17 fail. The record is not uniformly bad, but it is too uneven for a catalog-wide endorsement. Retatrutide is the cleanest current Loti signal, tirzepatide is a conditional verify-the-lot choice, and CJC-1295 plus semaglutide are clear weak spots. Middle-tier ratings also become less reassuring under stricter grading.

The corporate trail is a second reason to read Loti product by product. The storefront has domain history back to 2019, while state filings, DNS, email routing, and a site-interface capture point to a newer Florida operating wrapper. A predecessor entity with overlapping address and people helps explain continuity, but the public brand history and the current legal record do not line up cleanly.

Shared GA4, DNS, email, and Compliance Gate indicators tie Loti to a larger family of peptide and regulated-commerce storefronts, meaning several apparent vendor alternatives may not be independent supply-chain alternatives. Loti's COA page points to a Florida lab that exists as a separate LLC, but the reviewed materials did not show visible ISO 17025/A2LA accreditation, named analytical staff, or a stable public lab posture after an address change and relocation notice.

The report does not claim a confirmed enforcement action: no Loti-specific FDA warning letter was found in the field run, and service/shipping signals are comparatively strong. The risk sits in product dispersion, premium manufacturing claims without disclosed synthesis proof, a UK storefront with no matching Companies House entity found, and founder-style PR content that proved unreliable.

Inside the full report:

• Product-level lab narrative, rating trajectories, and methodology-divergence charts for all 6 tested peptides
• Florida filing trail for the operating LLC, predecessor vehicle, and COA laboratory
• DNS, GA4, email-routing, and Compliance Gate network map of related storefronts
• COA-lab review covering formation records, management, accreditation visibility, and address-change timing
• UK storefront check using Companies House searches and MHRA-reference evidence
• Reputation and pricing review across PeptideScores, forum captures, coupon surfaces, and BBB Scam Tracker

Risk assessment

• Product-quality risk for CJC-1295, Semaglutide and BPC-157 — high: Finnrick shows CJC-1295 at 5 tests with 0 pass / 5 fail and 19.21%, Semaglutide at 4 tests with 0 pass / 4 fail and 53.79%, and BPC-157 at 5 tests with 2 pass / 3 fail and 47.21%.
• Manufacturing and supply-chain transparency risk — high: Loti markets USA-made/manufacturer positioning, but reviewed records disclose no peptide-synthesis facility or API supplier and list Sterling Path at a residential Florida address.
• Multi-brand ownership-obscurity risk — high: Shared GA4, DNS, email and Compliance Gate infrastructure tie Loti Labs to at least nine related storefronts, so buyers may compare brands that are not independent.
• Vendor-COA credibility risk — medium: Loti COAs point to SR Biolabs, a Florida LLC formed in October 2023 with no visible ISO 17025/A2LA accreditation, no named analytical staff in reviewed pages, and a June 12, 2026 address-change/relocation.
• UK storefront compliance risk — high: The UK storefront claims domestic UK service and cites MHRA/UK medicines rules, but Companies House searches found no Loti Labs/Sterling Path UK entity or license.
• Corporate-history and founder-story opacity risk — medium: The current legal vehicle formed in August 2025 while the domain dates to 2019, no Loti Labs entity was found in Florida/Delaware, and 2025–2026 founder PR did not reliably disclose the operators.